

Effects of Intravenous Laser Irradiation of Blood on Pain, Function and Depression of Fibromyalgia Patients

Pin Yi Wu¹, I Wen Penn², Pei Hsin Lin³, Jia Chi Wang¹, Eric Chuang⁴, Szu Hsien Wu¹ and Tien Yow Chuang^{1*}

¹Department of Physical Medicine and Rehabilitation, National Yang-Ming University and Taipei Veterans General Hospital, Taipei, Taiwan

²Department of Physical Medicine and Rehabilitation, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan

³Department of Rehabilitation and Technical Aid Center, Taipei Veterans General Hospital, Taiwan

⁴Department of Integrative Biology Alumnus, University of California, Berkeley, USA

*Corresponding author: Tien Yow Chuang, Professor, Department of Physical Medicine and Rehabilitation, National Yang-Ming University and Taipei Veterans General Hospital, Taipei, Taiwan, Tel: 886-2-28757296; Fax: 886-2-28757359; E-mail: tychuang@vghtpe.gov.tw

Rec date: Feb 14, 2018; Acc date: Feb 28, 2018; Pub date: March 8, 2018

Copyright: © 2018 Pin YW, et al. this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: Fibromyalgia, labeled for an illness of wide spreading pain, fatigue, restless sleep, gastrointestinal disturbances, and mood disorders, is a complex and heterogeneous disease. Novel and improved treatments would allow healthcare professionals to improve the conditions of patients with fibromyalgia. For instance, photo biomodulation is a new treatment that minimizes heavy usage of drugs and side effects. This study investigated the clinical effects of intravenous laser irradiation of blood on pain, sleep, mood disorders, and quality of life in patients with fibromyalgia.

Methods: Fifteen patients diagnosed as having fibromyalgia based on the modified 2010 criteria of the American College of Rheumatology from an outpatient clinic were recruited. Before admission, all subjects were asked to submit visual analog scale (VAS), numbers of tender points, revised Fibromyalgia Impact Questionnaire (FIQR), revised Beck Depression Inventory (BDI) and Pittsburgh Sleep Quality Index (PSQI) according to their outcomes before/after drugs in a previous outpatient clinic. After admission, all participants received two courses of intravenous laser irradiation of blood, each course is composed of 10 intravenous laser irradiation of blood sessions, each session of the therapeutic duration lasted for 60 minutes. Two consecutive courses had a 7-day rest interval. The trial lasted for 4 weeks. Outcomes based on patient-reported symptoms of the aforementioned tests were evaluated on two separate occasions: baseline and within 24 hours after the last day of the protocol.

Results: The drugs resulted in significant reduction in pain intensity only. However, the before/after comparisons of intravenous laser irradiation of blood showed a significant improvement in VAS ($p=0.001$), number of tender points ($p=0.002$), FIQR ($p=0.001$), BDI ($p=0.003$) and PSQI ($p=0.01$). We also noted significantly positive effects of ILIB compared with drugs in all tests.

Conclusion: Intravenous laser irradiation of blood had a better effect on pain severity, sleep, mood disorder, and quality of life in patients with fibromyalgia. No unfavorable events were recorded; thus, intravenous laser irradiation of blood appears to be an effective treatment for patients with fibromyalgia.

Keywords: Fibromyalgia; Quality of life; Intravenous laser irradiation of blood; Photo biomodulation; Chronic pain syndrome; Laser; Pain

Introduction

Fibromyalgia, which is characterized by wide spreading pain, fatigue, restless sleep, gastrointestinal disturbances, and mood disorders, is a complex and heterogeneous disease [1-3]. However, its pathogenesis remains to be clearly established. Numerous professionals assume the role of central nervous system (CNS) pain processing abnormalities in fibromyalgia, including central sensitization and inadequate pain inhibition [4,5], and tonic peripheral nociceptive input associated with augmented windup and/or central sensitization in responses to neurotransmitters, genetic features, psychosocial changes, and environmental stress [4-6].

Clinicians and researchers have observed minimal progress in the treatments available for fibromyalgia within the last 20 years. Recent developments in the understanding of fibromyalgia would allow the identification of both pharmacological and non-pharmacological ways targeting specific active mechanisms of the disease, thereby enabling an effective management of the patients' conditions [7]. Moreover, new and improved treatments would allow healthcare professionals to improve the conditions of patients with fibromyalgia, which is often overlooked and grossly underfunded. For instance, photo biomodulation is a new treatment that minimizes heavy usage of drugs and side effects [8,9].

Low-level laser therapy (LLLT; topical laser) is one of the recent developments in the treatment of fibromyalgia [9-11]. LLLT can affect multiple signaling cascades and mechanisms associated with analgesia [12-14]. This therapeutic approach apparently increases β -endorphin levels, lymphatic flow, and blood supply. Moreover, researchers have

indicated that specific doses of LLLT could reduce blood lactate, oxidative stress, and inflammatory biomarker levels, which in turn limits inflammation, fatigue, and induces muscle relaxation [10,11,13,14].

However, because of the characteristic of pain and numerous tender points in patients with fibromyalgia, LLLT is typically performed for at least 20 minutes, moving from one tender point to another [9,11,15]. Intravenous laser irradiation of blood (ILIB), which is considered a safe therapeutic method, is more comfortable for patients. Another advantage of ILIB is that it requires less medical attention than the extracorporeal version [12,16,17]. In addition to the fundamental effects of LLLT, other integral influences of ILIB were also found, including positive effects on rheological properties of the blood, modulation of redox system in the mitochondria, and decreased oxidative stress makers [12,18]. Moreover, advantages of ILIB over LLLT can be expected as the former is more direct and less energy-consuming [16].

Currently, only two studies on “ILIB therapy patients with fibromyalgia are available”: one is a non-randomized interventional study [17] and the other is a single descriptive study [12]. Although current treatment guidelines for fibromyalgia support the core concept of patient-tailored, multicomponent therapy [19,20], in this study ILIB was used to investigate its therapeutic effect on pain, sleep condition, mood, and health-related quality of life (QOL).

Materials and Methods

Participants

All patients with fibromyalgia according to the modified 2010 criteria of the American College of Rheumatology (ACR) were recruited from an outpatient clinic in the Department of Rehabilitation and Physical Medicine, Taipei Veterans General Hospital, Taiwan [21,22]. Patients who had uncontrolled heart disease, who withdrew their participation because of personal reasons, and who were taking medications that caused sensitivity to light therapy (e.g. astemizole, estrogen, diclofenac, doxycycline) [23] were excluded.

Fifteen patients with fibromyalgia (all women) were included (mean age 53.77 years). Prior to hospital admission, all patients had been taking medications for at least 6 months and they were asked to provide pre-hospitalization data on pain intensity, depression and anxiety, sleep quality, and QOL. Most patients had tried one or more Food and Drug Administration-approved and/or off-label medications, such as pregabalin, duloxetine, and opioids. Most of the patients were advised to quit their medications if possible during admission; however, they were allowed to continue their current medications as they wish. This study was approved by our institution's human research committee and informed consent was obtained from all participants.

Protocol

All participants received two courses of ILIB; each course is composed of 10 ILIB sessions, and each therapeutic duration was 60 minutes. Two consecutive courses had a 7-day rest interval. During ILIB, each patient lay down in bed with supine position. A 24-gauge intravenous catheter was used for an elbow venous puncture (phlebotomy). The intravenous needle was subsequently replaced with a fiber-optic needle, which was inserted into the inner cannula of the intravenous catheter. The other side of the fiber optic needle was

connected to a helium-neon laser illuminator (YJ-ILIB-5, Bio-ILIB Human Energy Ltd, Taiwan), which emits red-light laser in continuous wave mode with a wavelength of 632.8 nm and a power output of 2.5 mW.

Measurements

Pain assessment

A visual analogue scale (VAS) was used to evaluate pain (0=no pain and 10=painful as imaginable) caused by fibromyalgia.

Depression and anxiety

The Revised Beck Depression Inventory (BDI) was employed for the assessment of depression. BDI is a widely used 21-item self-report inventory that measures the severity of depression in adolescents and adults [24].

Sleep quality

We used the Pittsburgh Sleep Quality Index (PSQI) to evaluate sleep conditions. It estimates sleep duration, sleep latency, and the frequency and severity of specific sleep-related problems during the past months. The index comprises 19 items which were grouped into 7 component scores, and weighted equally on a 4-point Likert scale, ranging from 0 (not during the past month) to 3 (≥ 3 times a week). The component scores are summed to yield a global PSQI score (ranges from 0–21), with higher scores indicating worse quality of sleep. Reliability estimates showed internal consistency of 0.83 for the 7 component scores, and test–retest reliability of 0.85 for the PSQI global scores [25].

Quality of life evaluation

The QOL of the patients with fibromyalgia was assessed using the Revised Fibromyalgia Impact Questionnaire (FIQR) [26], which contains three domains similar to those of the Fibromyalgia Impact Questionnaire (FIQ; function, overall impact, and symptoms). However, it differs from the FIQ as function questions were modified and questions on memory, tenderness, balance and environmental sensitivity were included. All questions are graded from 0 to 10. The FIQR is an updated version of the FIQ and has good psychometric properties, which could be easily scored and completed in 2 minutes.

The trial lasted for 4 weeks, and outcomes were evaluated on two separate occasions: baseline and within 24 hours after the last day of the protocol.

Statistical Analyses

Statistical analyses were performed with the SPSS 18.0 PC program. Results were expressed as mean $\pm$ S.D. Wilcoxon rank-sum test (featuring non-parametric statistics) was used to compare the measurements of therapeutic outcomes pre/ post treatments and the gain differences between the effects of drug and ILIB, including pain, tender point, quality of life, sleep quality, and depression. P values <0.05 were considered statistically significant.

Results

Table 1 showed the demographic characteristics of all the participants. Comorbidity, medication history and medication at admission were also shown in Table 1. All participants had received at least two types of drugs for fibromyalgia before admission. All the

participants were women with a mean age of 53.77 years (range: 31–64 years) and a mean body mass index of 24.30 (range: 17.9-32.65).

Subject	Sex	Age (year)	BMI	Fibromyalgia duration (year)	Comorbidity	Medication History	Medication admission at
1	F	31	17.9	3	Osteoarthritis	Neurontin 7 months	Nil
						Anxiedin 9 months	
2	F	56	21.5	7.5	Poliomyelitis	Dormicum 1 year	Flurbiprofen 5 years
						Lorazepam 1 year	
						Celecoxib 2 years	
3	F	51	20.3	9	Sicca syndrome; L4/5 Herniated intervertebral disc	Pregabalin 2 years	Estazolam 9 years
						Estazolam 9 years	Sertraline 8 years
						Sertraline 8 years	
						Xanax 3 months	
						Amitriptyline 4v	
						Ultracet 5 months	
						Celecoxib 5 months	
4	F	51	22.9	5	Depressive disorder; Breast Fibroadenoma	Amitriptyline 1 year	Vytorin 4 years
						Pregabalin 6 months	Lipanthyl 4 years
						Alprazolam 6 months	
						Meitifen 5 months	
5	F	59	29	5	Chronic migraine; in left Prolactinemia fossa; Major depression; L4/5 Spondylolisthesis	Remeron 4 years	Clonazepam 5 years
						Zopiclone 5 years	Flunarizine 4 years
						Flunarizine 4 years	Remeron 4 years
						Propranolol 4 years	Propranolol 4 years
						Clonazepam 5 years	Zopiclone 5 years
6	F	63	24.8	8	Rheumatoid arthritis; Osteoarthritis; Obstructive sleep apnea	Alprazolam 2 years	Salazine 6 years
						Salaxine 6 years	Eltroxin 6 years
						Zolpidem 8 years	Zolpidem 8 years
						Concor 1 year	Norvasc 3 years
						Clonazepam 1 year	
						Eltroxin 6 years	
7	F	62	30.4	4	Failed back surgery syndrome; L4/5 intervertebral disc	Pregabalin 2 years	Ultracet 3 years
						Ultracet 3 years	Celecoxib 1 year
						Celecoxib 1 year	Crestor 3 years
						Crestor 3 years	Isosorbide
						Isosorbide mononitrate 3 years	mononitrate 3 years
8	F	64	30.5	4	Sicca syndrome; L4/5/S1 spinal stenosis	Trazodone 7 months	Aspirin 1 year

					mitral, aortic, and tricuspid regurgitation; hypertension; cataract	Clonazepam 2 years	Crestor 1 year
						Diclofenac 7 months	Prednisolone 2 years
						Pregabalin 1 year	
						Prednisolone 2 years	
9	F	54	22.3	1	Systemic erythematous; ankylosing spondylitis	Pregabalin 4 months	Propranolol 6 months
						Propranolol 6 months	
10	F	51	22.7	7	Left breast mixed invasive ductal carcinoma, s/p modified radical mastectomy, s/p CCRT; L-spine spondylosis	Clonazepam 2 years	Estazolam 7 years
						Zolpidem 4 years	
						Estazolam 7 years	
						Lorazepam 6 months	
						Pregabalin 2 years	
						Imipramine 1 year	
						Amitriptyline 3 years	
11	F	63	32.7	7	Type 2 Diabetes Mellitus; metabolic syndrome; stress urinary incontinence; L4/5 Spondylolisthesis	Glucophage 5 years	Copidogre 8 years
						Simvastatin 6 years	Insulin 2 years
						Flunarizine 4 months	Olmotec 4 years
						Glimepiride 4 years	Plaquenil 1 year
						Lorazepam 2 years;	Prednisolone 1 year
						Losartan 2 years	Simvastatin 6 years
						Copidogre 8 years	
12	F	50	19.7	4	Complex regional pain syndrome	Pregabalin 1 years	Ultracet 3 years
						Celecoxib 1 years	
						Ultracet 3 years	
						Tramadol 7 months	
						Baclofen 1 months	
						Etoricoxib 7 months	
13	F	50	20.7	15	Multiple sclerosis; Retractable migraine; Psoriasis vulgaris; bilateral optic neuropathy; major depression; Iron deficiency anemia	Meloxicam 6 months	Zolpidem 10 years
						Modipanol 4 years	Ultracet 5 years
						Zolpidem 10 years	Imigran 1 year
						Quetiapine 10 years	Quetiapine 10 years
						Duloxetine 9 years	Morphin 6 years
						Ultracet 5 years	Modipanol 4 years
						Topamax 8 months	Duloxetine 9 years
						Flunarizine 2 months	Amantadine 6 years
						Pregabalin 7 months	

						Morphine 6 years	
						Amantadine 6 years	
14	F	68	28		Rheumatoid arthritis; T-L spine degenerative joint disease with spur formation; hepatocellular carcinoma S3, pT2Nx, Stage II, s/p segmentectomy and transcatheter arterial chemoembolization	Lorazepam 2 years;	Alprazolam 5 years
						Alprazolam 5 years	Norvasc 4 years
						Prednisolone 2 months	Fludiazepam 1 year
						Sulfasalazine 2 months	Valsartan 3 years
						Etoricoxib 3 months;	
15	F	45	17.9	11	Sicca syndrome; peptic ulcer; iron deficiency anemia; Irritable bowel syndrome	Ultracet 8 years	Ultracet 8 years
						Amitriptyline 7 months	
						Pregabalin 3 months;	
						Clonazepam 2 years	

Table 1: Demographic and clinical characteristics of the study population.

Table 2 presented the measured outcomes before and after the treatment. The drugs therapy before admission achieved significance in VAS ($p=0.006$) only. However, all tests including VAS ($p=0.001$), numbers of tender points ($p=0.002$), FIQR ($p=0.001$), BDI ($p=0.003$)

and PSQI ($p=0.01$) reached significance after the ILIB intervention. Moreover, comparing with drugs, the ILIB therapy demonstrated significantly positive effects on pain intensity, mood, sleep quality and QOL.

Measurements	Medication + exercise (Pre/Post)	ILIB + exercise (Pre/Post)	Difference (p-value)
VAS	$8.00 \pm 1.4/6.93 \pm 1.8^*$	$7.80 \pm 2.0/4.73 \pm 2.0^{**}$	0.006
Tender point	$15.13 \pm 3.7/14.53 \pm 4.2$	$14.00 \pm 4.0/10.73 \pm 5.7^{**}$	0.038
FIQR	$75.86 \pm 20.5/69.17 \pm 22.0$	$77.14 \pm 17.0/49.93 \pm 20.5^{**}$	0.005
BDI	$20.40 \pm 9.8/19.73 \pm 10.0$	$19.93 \pm 9.7/10.46 \pm 7.1^{**}$	0.016
PSQI	$15.60 \pm 3.5/15.26 \pm 4.1$	$14.60 \pm 3.4/11.46 \pm 4.9^*$	0.027

Results are expressed as mean $\pm$ standard deviation (SD), * $p<0.05$; ** $p<0.005$ Abbreviation: ILIB: Intravenous Laser Irradiation of Blood, VAS: Visual Analogue Scale, FIQR: Revised Fibromyalgia Impact Questionnaire, BDI: Revised Beck Depression Inventory, PSQI: Pittsburgh Sleep Quality Index

Table 2: Wilcoxon tests for pre and post-intervention comparisons and the differences between the two treatments.

Figures 1-5 portrayed the distributions of all measurements before and after medication and intravenous laser irradiation, which also highlighted the significant results in Wilcoxon tests.

Figure 1 displayed the Wilcoxon tests of VAS scores, which reached significance in both the intra-group comparisons and the differences between the two treatments.

Figure 2 demonstrate the number of tender points before and after medication and intravenous laser irradiation, and the Wilcoxon test achieved significance in laser group and the differences between the two treatments.

Figures 3-5 possessed similar Wilcoxon result as Figure 2, and they showed the distributions of the FIQR scores, the BDI scores, and the PSQI scores, separately.




Figure 1: The distributions of VAS scores before and after medication and intravenous laser irradiation. Abbreviation: M: medication; L: Intravenous Laser Irradiation of Blood (ILIB); VAS: Visual Analogue Scale




Figure 2: Number of tender points before and after medication and intravenous laser irradiation.
Abbreviation: M: Medication; L: Intravenous Laser Irradiation of Blood (ILIB)




Figure 3: The distributions of FIQR scores before and after medication and intravenous laser irradiation.
Abbreviation: M: Medication; L: Intravenous Laser Irradiation of Blood (ILIB); FIQR: Revised Fibromyalgia Impact Questionnaire.




Figure 4: The distributions of BDI scores before and after medication and intravenous laser irradiation.
Abbreviation: M: Medication; L: Intravenous Laser Irradiation of Blood (ILIB); BDI: Revised Beck Depression Inventory.




Figure 5: The distributions of PSQI scores before and after medication and intravenous laser irradiation.
Abbreviation: M: Medication; L: Intravenous Laser Irradiation of Blood (ILIB); PSQI: Pittsburgh Sleep Quality Index

Discussion

The etiology of fibromyalgia remains enigmatic and treatment results are often unsatisfactory. Currently, no cure for fibromyalgia exists. A multifaceted attempt tailored to the patients' needs is a crucial element in the treatment of pain, fatigue, and other diverse symptoms. Thus, ILIB has been widely used for its analgesic, spasmolytic, and sedative abilities [12,16].

Our findings showed that the maximum pain intensity significantly decreased after the ILIB therapy. Previous meta-analyses have shown that red laser phototherapy effectively relieves pain through several etiologies, thereby making it a valuable tool for pain management [27,28]. In addition, the ILIB therapy had effects on peripheral neural stimulation, the regulation of microcirculation, and interrupting persistent pain, and it promotes analgesia [12,29]. The hallmark of ILIB therapy encompasses concepts of physical, biochemical mechanisms, tissue photobiology, vasodilation via increasing localized nitric oxide production, and cell signaling [12,29-34].

Non-restorative sleep, fatigue, and depression are common among patients with fibromyalgia, which is possibly due to the pathophysiology of central sensitization [3,19,35,36]. We observed that patients treated with ILIB had marked improvement in quality of life, sleep, and mood disorders, which was possibly mediated by soluble mediators such as endorphins and serotonin [31,37-39]. The increase in total body serotonin, including CNS serotonin after red light laser [38,39], could have partially contributed to the improvement in pain, mood, and sleep improvements. In addition, research showed that mitochondrial impairment possibly has a significant effect causing the dysfunction of regulatory system cells, such as the nervous, endocrine, and lymphatic cells and their communicative network [40]. Hence, pain, mood disorders and sleep are prevalent in fibromyalgia. With ILIB, the redox system appears to be modulated resulting in ATP production and reduction in the generation of free radicals and super oxidants [12,18] which could be related to the antioxidant defenses in patients with fibromyalgia. Delayed skeletal muscle fatigue and better exercise performance may also be associated with the recovery from oxidative stress [15,41].

Moreover, the majority of patients in our study used a wide range of medications (e.g. pregabalin, duloxetine, tricyclic antidepressants, and non-steroidal anti-inflammatory drugs) for pain relief, fatigue, and

other symptoms. However, the relief felt from any single drug is minimal and most of the patients experienced side effects. By contrast, no complaints of discomfort were observed in all patients who had ILIB therapy.

Despite our efforts to reduce selection bias and to reduce confounding variables in our subjects by employing a vast collection of medical profiles, this study still has some limitations. No gold standard diagnostic biomarkers for fibromyalgia exist; thus, physicians only depend on patient-reported symptoms in understanding the complexities of this condition. Consequently, recall bias was not prevented in this study. Further studies may need prospective designs with randomized controls to limit recall bias.

Conclusion

This pilot study demonstrates that ILIB could lessen the effects of fibromyalgia, by improving pain severity, mood, sleep conditions, and quality of life. Hence, ILIB is a potential therapeutic regimen for patients with fibromyalgia.

Conflict of Interest

All authors declare that there is no conflict of interest.

Acknowledgment

The authors thank the editor and series editor for constructive criticisms of an earlier version of this manuscript.

References

- Kashikar ZS, Graham TB, Huenefeld MD, Powers SW (2000) A review of biobehavioral research in juvenile primary fibromyalgia syndrome. *Arthritis Care Res* 13: 388-397.
- Theoharides TC, Tsilioni I, Arbetman L, Panagiotidou S (2015) Fibromyalgia syndrome in need of effective treatments. *J Pharmacol Exp Ther* 355: 255-263.
- Chinn S, Caldwell W, Gritsenko K (2016) Fibromyalgia pathogenesis and treatment options update. *Curr Pain Headache* 20: 25.
- Staud R (2006) Biology and therapy of fibromyalgia: Pain in fibromyalgia syndrome. *Arthritis Res Ther* 8: 208.
- Woolf CJ (2011) Central sensitization: Implications for the diagnosis and treatment of pain. *Pain* 152: 2-15.
- Littlejohn G (2015) neurogenic neuro inflammation in fibromyalgia and complex regional pain syndrome. *Nat Rev Rheumatol* 11: 639.
- Schmidt WT, Diers M (2017) new insights into the pathophysiology and treatment of fibromyalgia. *Biomed* 5: 22.
- Herpich CM, Leal-Junior EC, Amaral AP, de Paiva Tosato J, dos Santos Glória IP, et al. (2014) Effects of phototherapy on muscle activity and pain in individuals with temporomandibular disorder: A study protocol for a randomized controlled trial. *Trials* 15: 491.
- Da Silva MM, Albertini R, Leal-Junior EC, De Carvalho PD, Silva JA, et al. (2015) Effects of exercise training and photobiomodulation therapy (EXTRAPHOTO) on pain in women with fibromyalgia and temporomandibular disorder: Study protocol for a randomized controlled trial. *Trials* 16: 252.
- Gür A, Karakoc M, Nas K, Cevik R, Sarac J, et al. (2002) Efficacy of low power laser therapy in fibromyalgia: A single-blind, placebo-controlled trial. *Lasers Med Sci* 17: 57-61.
- Ruaro JA, Fréz AR, Ruaro MB, Nicolau RA (2014) Low-level laser therapy to treat fibromyalgia. *Lasers in medical science* 29: 1815-1859.
- Momenzadeh S, Abbasi M, Ebadifar A, Aryani M, Bayrami J, et al. (2015) The intravenous laser blood irradiation in chronic pain and fibromyalgia. *Journal of lasers in medical sciences* 6: 6.
- Dube A, Bansal H, Gupta PK (2003) Modulation of macrophage structure and function by low level He-Ne laser irradiation. *Photochem Photobiol Sci* 2: 851-855.
- Funk JO, Kruse A, Kirchner H (1992) Cytokine production after helium neon laser irradiation in cultures of human peripheral blood mononuclear cells. *J Photochem Photobiol B* 16: 347-355.
- De Marchi T, Junior EC, Bortoli C, Tomazoni SS, Lopes-Martins RÁ, et al. (2012) Low-level laser therapy (LLLT) in human progressive-intensity running: Effects on exercise performance, skeletal muscle status, and oxidative stress. *Lasers Med Sci* 27: 231-236.
- Momenzadeh S, Akhyani V, Razaghi Z, Ebadifar A, Abbasi M, et al. (2016) Evaluation of the effects of intravenous and percutaneous low level laser therapy in the management of shoulder myofascial pain syndrome. *J Lasers Med Sci* 7: 16.
- Torsten E, Wieden MD (2008) Fibromyalgia in pain therapy: Mechanisms and treatment options in laser therapy. *Schmerz & Akupunktur* 34: 130-136.
- Huang SF, Tsai YA, Wu SB, Wei YH, Tsai PY, et al. (2012) Effects of intravascular laser irradiation of blood in mitochondria dysfunction and oxidative stress in adults with chronic spinal cord injury. *Photomed Laser Surg* 30: 579-586.
- Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, et al. (2012) Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: Executive summary. *Pain Res Manag* 18:119-126.
- Ablin J, Fitzcharles MA, Buskila D, Shir Y, Sommer C, et al. (2013) Treatment of fibromyalgia syndrome: Recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. *Evid Based Complement Alternat Med* 2013.
- Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, et al. (2010) The american college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care Res* 62: 600-610.
- Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, et al. (2011) Fibromyalgia criteria and severity scales for clinical and epidemiological studies: A modification of the ACR preliminary diagnostic criteria for fibromyalgia. *J Rheumatol* 38: 1113-1122.
- http://www.nj.gov/health/ceohs/documents/phss/fda_photosensitivitylist.pdf
- Kühner C, Bürger C, Keller F, Hautzinger M (2007) Reliability and validity of the revised beck depression inventory (BDI-II). results from german samples. *NERVENARZT* 78: 651-656.
- Buyse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ, et al. (1989) The pittsburgh sleep quality index: A new instrument for psychiatric practice and research. *Psychiatry Res* 28: 193-213.
- Bennett RM, Friend R, Jones KD, Ward R, Han BK, et al. (2009) The revised fibromyalgia impact questionnaire (FIQR): Validation and psychometric properties. *Arthritis Res Ther* 11: R120.
- Fulop AM, Dhimmer S, Deluca JR, Johanson DD, Lenz RV, et al. (2010) A meta-analysis of the efficacy of laser phototherapy on pain relief. *The Clinical journal of pain* 26: 729-736.
- Jang H, Lee H (2012) Meta-analysis of pain relief effects by laser irradiation on joint areas. *Photomed Laser Surg* 30: 405-417.
- Brill GE, Grigoriev SN, Romanova TP (1993) Changes of leucocyte metabolism in HeNe laser blood irradiation in vitro. in optical methods of biomedical diagnostics and therapy 1981: 204-210.
- Boev SS, Selivonenko VG (1997) The impact of the intravenous He-Ne laser therapy on the antioxidant system in patient with stable exertion angina and postinfarct cardiosclerosis. *Klinicheskaia meditsina*.75: 30-33.
- Weber MH, Fuganger May T, Wolf T (2007) The intravenous laser blood irradiation – introduction of a new therapy. *J Lasers Med Sci* 50: 12-23.

32. Karu TI, Pyatibrat LV, Kolyakov SF, Afanasyeva NI (2008) Absorption measurements of cell monolayers relevant to mechanisms of laser phototherapy: Reduction or oxidation of cytochrome c oxidase under laser radiation at 632.8 nm. *Photomed Laser Surg* 26: 593-599.
33. Mitchell UH, Mack GL (2013) Low-level laser treatment with near-infrared light increases venous nitric oxide levels acutely: A single-blind, randomized clinical trial of efficacy. *Am J Phys Med Rehabil* 92: 151-156.
34. Samoilova KA, Zhevago NA, Petrishchev NN, Zimin AA (2008) Role of nitric oxide in the visible light-induced rapid increase of human skin microcirculation at the local and systemic levels: II. healthy volunteers. *Photomed Laser Surg* 26: 443-449.
35. Cassisi G, Sarzi PP, Alciati A, Casale R, Bazzichi L, et al. (2008) Symptoms and signs in fibromyalgia syndrome. *Reumatismo* 60:15-24.
36. Schmidt Wilcke T, Clauw DJ (2011) Fibromyalgia: From pathophysiology to therapy. *Nat Rev Rheumatol* 7: 518.
37. Bjordal JM, Johnson MI, Iversen V, Aimbire F, Lopes-Martins RA, et al. (2006) Low-level laser therapy in acute pain: A systematic review of possible mechanisms of action and clinical effects in randomized placebo-controlled trials. *Photomed Laser Ther* 24: 158-168.
38. Tomaz de MM, Núñez SC, Kato IT, Ribeiro MS (2016) Light therapy modulates serotonin levels and blood flow in women with headache: A preliminary study. *Exp Biol Med* 241: 40-45.
39. Walker J (1983) Relief from chronic pain by low power laser irradiation. *Neurosci Lett* 43: 339-344.
40. Cordero MD, Alcocer Gómez E, Cano García FJ, De Miguel M, Carrión AM, et al. (2011) Clinical symptoms in fibromyalgia is better associated to lipid peroxidation levels in blood mononuclear cells rather than in plasma. *PLoS ONE* 6: e26915.
41. Borsa PA, Larkin KA, True JM (2013) Does phototherapy enhance skeletal muscle contractile function and postexercise recovery? A systematic review. *J Athl Train* 48: 57-67.